1. At a Glance – Blink and You’ll Miss the Growth
₹15,239 crore market cap. ₹1,862 stock price. 53× trailing P/E.
And yet, Q3 FY26 just walked in wearing a leather jacket and said: “Hold my reactor.”
Acutaas Chemicals clocked ₹3,932 million revenue in Q3 FY26, up 43% YoY, while PAT exploded 134% YoY to ₹1,062 million. Operating margin? 38%. Debt? Practically extinct at ₹8.35 crore. ROCE sitting at ~20%, ROE at 16%, and exports contributing ~74% of revenue.
This isn’t a sleepy API intermediate supplier anymore. This is a company doing pharma intermediates + specialty chemicals + semiconductors + battery chemicals, while casually dropping MoUs worth ₹530 crore and installing solar plants on the side like it’s a weekend hobby.
Stock is expensive. Promoters have diluted. But earnings are sprinting faster than valuation cops can catch them.
So the real question is:
Is Acutaas overpriced brilliance… or just getting started?
2. Introduction – From “API Supplier” to “Strategic Molecule Mafia”
Once upon a time, Acutaas (earlier Ami Organics) was known for advanced pharma intermediates. Solid business, boring pitch decks, decent margins.
Then management woke up one day and said:
“Why stop at intermediates when we can become mission critical?”
Fast forward to FY25–FY26, and this company is now:
- Supplying 550+ pharma intermediates
- Holding 50–90% market share in key molecules
- Entering electrolytes for battery cells
- Making semiconductor-grade chemicals
- Running CDMO projects targeting ₹1,000 crore revenue by FY28
And all of this is happening without leverage, while margins are expanding instead of collapsing (which is rare in chemical land).
The market noticed. Stock doubled in a year. Mutual funds and sovereign funds showed up. And
